Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2005

View Archived Issues

Small Bone Innovations launches thumb arthritis implant from Artimplant

Allograft bone plus rhBMP-2 shows promise in diaphyseal tibial fractures

rhBMP-2 formulation enhances lumbar spine fusion

Sustained-release epidural morphine effective in reducing knee surgery pain

Retaane safe in patients with macular degeneration

Acyline induces long-term gonadotropin, testosterone suppression

Multiple aviscumine doses evaluated in phase I trial in advanced cancer patients

Aldose reductase inhibitors recommended for diabetic neuropathy

Avian flu clinical trials to begin next month for Alferon N

Clinical studies evaluate the PK profile of febuxostat

BAY-43-9006 under phase II clinical evaluation for AIPC

Testosterone suppression reported with abiraterone acetate in prostate cancer patients

CC-4047 found to decrease PSA levels in patients with HRPC

Avastin shows promise for wet AMD

Complete and partial responses in phase I/II study of MDX-010 for metastatic melanoma

Seroquel findings reported at AAGP meeting

Enrollment completed in pivotal study of five-day Factive for CAP

Johnson & Johnson to acquire TransForm Pharmaceuticals

Ceplene designated orphan drug in Europe for AML

Enrollment completed in three-year Enteryx procedure trial

DNA testing may improve safety of Strattera

Pharming expands hereditary angioedema trials of rhC1INH to Canada

sanofi pasteur launches preservative-free formulation of pediatric flu vaccine

Zila's OraTest clinical program amendments draw preliminary FDA comments

Age and gender do not affect pharmacokinetics of solifenacin

Clinical candidate for depression, anxiety and ADHD presented at the ACS meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...